Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway

Cancer Letters

Volumn 355, Issue 2, 2014, Pages 201-209

  Li, Maolan ^a,b   Lu, Jianhua ^a,b   Zhang, Fei ^a,b   Li, Huaifeng ^a,b   Zhang, Bingtai ^c   Wu, Xiangsong ^a,b   Tan, Zhujun ^a,b   Zhang, Lin ^a,b   Gao, Guofeng ^c   Mu, Jiasheng ^a,b   Shu, Yijun ^a,b   Bao, Runfa ^a,b   Ding, Qichen ^a,b   Wu, Wenguang ^a,b   Dong, Ping ^a,b   Gu, Jun ^a,b   Liu, Yingbin ^a,b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle arrest; Cell proliferation; Gallbladder cancer; RNA interference; YAP1

Indexed keywords

AXL PROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN 1; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AXL GENE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GALLBLADDER CANCER; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; YES ASSOCIATED PROTEIN 1 GENE; ANIMAL; BIOSYNTHESIS; CELL CYCLE S PHASE; CELL NUCLEUS; ENZYME ACTIVATION; GALLBLADDER TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; ENZYME ACTIVATION; GALLBLADDER NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENES; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; S PHASE;

EID: 84908152600     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.036     Document Type: Article

References (29)

1. Randi G., Franceschi S., La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int. J. Cancer 2006, 118:1591-1602.
2. Srivastava K., Srivastava A., Sharma K.L., Mittal B. Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis. Mutat. Res 2011, 728:67-79.
3. Boutros C., Gary M., Baldwin K., Somasundar P. Gallbladder cancer: past, present and an uncertain future. Surg. Oncol 2012, 21:e183-e191.
4. Wistuba I.I., Gazdar A.F. Gallbladder cancer: lessons from a rare tumour. Nat. Rev. Cancer 2004, 4:695-706.
5. Wang J.W., Peng S.Y., Li J.T., Wang Y., Zhang Z.P., Cheng Y., et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett 2009, 281:71-81.
6. Katoh M. Function and cancer genomics of FAT family genes (review). Int. J. Oncol 2012, 41:1913-1918.
7. Sudol M., Recinos C.C., Abraczinskas J., Humbert J., Farooq A. WW or WoW: the WW domains in a union of bliss. IUBMB Life 2005, 57:773-778.
8. Xie Q., Chen J., Feng H., Peng S., Adams U., Bai Y., et al. YAP/TEAD-mediated transcription controls cellular senescence. Cancer Res 2013, 73:3615-3624.
9. Baia G.S., Caballero O.L., Orr B.A., Lal A., Ho J.S., Cowdrey C., et al. Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol. Cancer Res 2012, 10:904-913.
10. Lee S.E., Lee J.U., Lee M.H., Ryu M.J., Kim S.J., Kim Y.K., et al. RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis 2013, 2:e55.
11. Lim B., Park J.L., Kim H.J., Park Y.K., Kim J.H., Sohn H.A., et al. Integrative genomics analysis reveals the multilevel dysregulation and oncogenic characteristics of TEAD4 in gastric cancer. Carcinogenesis 2014, 35:1020-1027.
12. Tschaharganeh D.F., Chen X., Latzko P., Malz M., Gaida M.M., Felix K., et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013, 144:1530-1542.
13. Sun P.L., Kim J.E., Yoo S.B., Kim H., Jin Y., Jheon S., et al. Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment. Ann. Surg. Oncol 2014, 10.1245/s10434-014-3715-5.
14. Zhao Y., Zhou W., Xue L., Zhang W., Zhan Q. Nicotine activates YAP1 through nAChRs mediated signaling in esophageal squamous cell cancer (ESCC). PLoS ONE 2014, 9:e90836.
15. Martianov I., Cler E., Duluc I., Vicaire S., Philipps M., Freund J.N., et al. TAF4 inactivation reveals the 3 dimensional growth promoting activities of collagen 6A3. PLoS ONE 2014, 9:e87365.
16. Liu A.M., Xu M.Z., Chen J., Poon R.T., Luk J.M. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin. Ther. Targets 2010, 14:855-868.
17. Xu M.Z., Chan S.W., Liu A.M., Wong K.F., Fan S.T., Chen J., et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011, 30:1229-1240.
18. Pinheiro C., Longatto-Filho A., Scapulatempo C., Ferreira L., Martins S., Pellerin L., et al. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008, 452:139-146.
19. Yu S.J., Hu J.Y., Kuang X.Y., Luo J.M., Hou Y.F., Di G.H., et al. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin. Cancer Res 2013, 19:1389-1399.
20. Linger R.M., Cohen R.A., Cummings C.T., Sather S., Migdall-Wilson J., Middleton D.H., et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2013, 32:3420-3431.
21. Chen D., Sun Y., Wei Y., Zhang P., Rezaeian A.H., Teruya-Feldstein J., et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med 2012, 18:1511-1517.
22. Green D.R., Evan G.I. A matter of life and death. Cancer Cell 2002, 1:19-30.
23. Lee M.H., Huang Z., Kim D.J., Kim S.H., Kim M.O., Lee S.Y., et al. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev. Res 2013, 6:455-465.
24. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
25. Wang X., Saso H., Iwamoto T., Xia W., Gong Y., Pusztai L., et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 2013, 73:6516-6525.
26. Paccez J.D., Vogelsang M., Parker M.I., Zerbini L.F. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int. J. Cancer 2014, 134:1024-1033.
27. Pinato D.J., Mauri F.A., Lloyd T., Vaira V., Casadio C., Boldorini R.L., et al. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Br. J. Cancer 2013, 108:621-628.
28. Park H.J., Baen J.Y., Lee Y.J., Choi Y.H., Kang J.L. The TAM-family receptor Mer mediates production of HGF through the RhoA-dependent pathway in response to apoptotic cells. Mol. Biol. Cell 2012, 23:3254-3265.
29. Yuan M., Tomlinson V., Lara R., Holliday D., Chelala C., Harada T., et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008, 15:1752-1759.